Akcea Therapeutics Inc (NASDAQ: AKCA) is having an overwhelmingly rough start to the trading session this morning after the company announced that the FDA rejected a treatment it was hoping to get approved in partnership with Ionis Pharmaceuticals Inc (NASDAQ: IONS). Of course, the rejection upset investors, sending the stock tumbling down. Today, we’ll talk about: … Read more
Ionis Pharmaceuticals Inc (NASDAQ: IONS) is headed for the top in the pre-market hours this morning after announcing an expanded collaboration with Biogen Inc (NASDAQ: BIIB). Of course, the news that the collaboration between the two companies is expanding is exciting to investors who are pushing the stock upward. Today, we’ll talk about: The expanded collaboration; … Read more
Ionis Pharmaceuticals Inc (NASDAQ: IONS) is having an incredibly rough start to the trading session today, and for good reason. The company released data from a key clinical trial, and while the data seemed positive at first, side effects proved to be a source of fear for investors. As a result, the stock is taking … Read more